Passage BIO (PASG) Cash from Operations (2019 - 2026)
Passage BIO (PASG) posted quarterly Cash from Operations of 12987000.0 for Q1 2026, up 6.21% year-over-year from 12227577.96 in Q1 2025, and down 100.45% quarter-over-quarter from 6479000.0 in Q4 2025.
Passage BIO (PASG) Cash from Operations (2019 - 2026) Analysis & Trends
Passage BIO's Cash from Operations history runs 8 years deep, the most recent figure standing at 12987000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 6.21% year-over-year to 12987000.0; the TTM figure through Mar 2026 stood at 30649000.0 (up 28.51% YoY), while the FY2025 annual figure was 31509000.0, up 34.3% from the prior year.
- Cash from Operations for Q1 2026 stood at 12987000.0, down from 6479000.0 in the prior quarter.
- The five-year high for Cash from Operations was 4853000.0 in Q3 2025, with the low at 44711000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 17139000.0 (2023), against an average of 16995647.06.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations slumped 45.55% in 2022, then jumped 61.14% in 2024.
- Passage BIO's Cash from Operations stood at 24021000.0 in 2022, then grew by 18.75% to 19516000.0 in 2023, then jumped by 56.73% to 8444000.0 in 2024, then gained by 23.27% to 6479000.0 in 2025, then plunged by 100.45% to 12987000.0 in 2026.
- Business Quant data shows PASG's Cash from Operations at 12987000.0 in Q1 2026, 6479000.0 in Q4 2025, and 4853000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | -9.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.18 Mn |
| Jun 30, 2026 | -9.18 Mn |
| Mar 31, 2026 | -12.99 Mn |
| Mar 31, 2026 | -12.99 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -8.44 Mn |
| Dec 31, 2024 | -8.44 Mn |
| Sep 30, 2024 | -7.45 Mn |
| Sep 30, 2024 | -7.45 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Mar 31, 2024 | -18.93 Mn |
| Mar 31, 2024 | -18.93 Mn |